Abstract Background: Investigators were suspicious of tyrosine-methionine-aspartate-aspartate (YMDD) mutations occurred only in patients who were treated by lamivudine. However, YMDD mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines was reported in some studies. The aim of this study was to evaluate YMDD mutations in Ira...

YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD variants were detected by polymerase chain reaction (PCR) and restriction fragment-lengt...

AIM To polymerase P region (YMDD) mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines and to explore its correlation with pre-c-zone mutations, HBV genotypes and HBV DNA level, and to observe its curative effect. METHODS A total of 104 cases (38 cases in group of familial aggregation and 66 cases in group of non-familial ...

abstract background: investigators were suspicious of tyrosine-methionine-aspartate-aspartate (ymdd) mutations occurred only in patients who were treated by lamivudine. however, ymdd mutations of hepatitis b virus gene (hbv dna) in patients with chronic hepatitis b (chb) untreated with antiviral medicines was reported in some studies. the aim of this study was to evaluate ymdd mutations in iran...

BACKGROUND Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy. This paper aims to assess the overall spontaneous incidence and related risk factors of YMDD-motif mutations among lamivudine-naïve chronic HBV carriers,...

amivudine (LAM), a nucleoside analog, was the first anti-HBV rug approved for antiviral therapy in China. Long-term antivial therapy with LAM may lead to drug resistance, which is ssociated with a mutation in tyrosine-methionine-aspartic cid-aspartic acid (YMDD) motif of the reverse transcripase in HBV-DNA genome. Several previous studies showed hat YMDD mutations were also present in treatment...